Drug Product Recalls In 2011: Categorized By Problem Area
This article was originally published in The Gold Sheet
Executive Summary
This table lists every drug recall of 2011, along with a description of the drug product, the manufacturer, the recaller, the recall class and the reason for the recall.
You may also be interested in...
Contamination is Major Problem Seen in GMP Warning Letters
FDA’s aggressive enforcement against pharmaceutical manufacturers for GMP violations continued in the first half of the year through its use of warning letters. Inadequate contamination controls was a common deficiency found in eight of the 18 drug GMP warning letters, failure to investigate out-of-specification results continues to be the most frequent GMP deficiency in warning letters, and cites of stability problems are increasing.
Contamination Issues Drove Drug Recalls to Record Levels in 2011
How contamination, sterility assurance, OOS and other issues caused drug recalls to spike again last year. What happened at Aidapak, H&P, Ben Venue, Hospira, Teva and other manufacturers to set a new record.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.